7‐Day Triple Therapy of <i>Helicobacter pylori</i> Infection with Levofloxacin, Amoxicillin, and High‐Dose Esomeprazole in Patients with Known Antimicrobial Sensitivity

Abstract

The data of this pilot study suggest a better than 80% efficacy of the new 7-day levofloxacin triple therapy, which is within the range of the French triple therapy in patients with MET- and CLA-susceptible strains. The data suggest that the new levofloxacin triple therapy may also be an option in patients with MET- and CLA-resistant H. pylori strains.